Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec and Paclitaxel in Elderly Patients With Advanced NSCLC
NCT01011075Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2009
- Primary completion
- Jul 2011
- Countries
- 1
- Drugs
- imatinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label trial of imatinib in non-small cell lung cancer (NSCLC), sponsored by New Mexico Cancer Research Alliance. Primary endpoint: Response Rate at 6 months. Started Aug 2009; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients aged 70 or older with Stage IIIB (with pleural effusion) or Stage IV non-small cell lung cancer, ECOG 0-2, and no prior chemotherapy for advanced disease.
04
Endpoints
Primary
Response Rate
Beyond the preview
Go deeper on NCT01011075.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011075.